Spinifex investors to exit as Novartis agrees to $200m-plus buyout

Novo A/S, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and the University of Queensland will shortly exit their investments in Spinifex Pharmaceuticals, as Novartis International AG has agreed to buy it for $200m cash, "plus undisclosed clinical development and regulatory milestone payments".